Related Experiment Videos
Treatment of childhood acute nonlymphoblastic leukemia: a review
1Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Insights
Treatment for acute nonlymphoblastic leukemia (ANLL) in children remains challenging. Current induction chemotherapy achieves remission in 80% of pediatric ANLL patients, with ongoing research exploring novel agents and optimizing maintenance therapy.
Area of Science:
- Pediatric Oncology
- Hematology
- Cancer Treatment Research
Background:
- Treatment recommendations for acute nonlymphoblastic leukemia (ANLL) in children are conflicting.
- Long-term survival for children with ANLL ranges from 35-50%.
Purpose of the Study:
- To review current treatment strategies for pediatric ANLL.
- To discuss advancements in induction chemotherapy, maintenance therapy, and bone marrow transplantation.
Main Methods:
- Review of existing clinical trials and treatment guidelines for pediatric ANLL.
- Analysis of remission rates, survival data, and transplantation outcomes.
Main Results:
- Induction chemotherapy (cytarabine and daunorubicin) achieves remission in approximately 80% of pediatric ANLL cases.
- Shortening maintenance therapy has not negatively impacted outcomes in pediatric trials.
- Allogeneic bone marrow transplantation (BMT) shows the best disease-free survival (55-65%), despite risks like chronic graft-versus-host disease (GvHD).
- Autologous BMT outcomes are improving with evolving protocols.
Conclusions:
- Further research is needed to establish optimal induction and maintenance therapy durations for pediatric ANLL.
- Allogeneic BMT offers the best chance for long-term survival but requires careful management of GvHD.
- Advancements in autologous BMT may provide an alternative treatment option.
Abstract:
Recommendations for the treatment of ANLL in general, and in pediatrics more specifically, are still conflicting. Overall, a child diagnosed with ANLL has a 35-50% of remaining alive long term, without disease. Induction chemotherapy with cytarabine and daunorubicin will achieve remission in about 80% of children with ANLL. So far, intensifying induction chemotherapy by adding more agents has not changed this result significantly. Major changes in induction chemotherapy may come from either new chemotherapeutic agents or biological agents that hasten bone marrow recovery after treatment. Such an approach might allow more dose-intensive drug administration without increased toxicity. Another question that is slowly being answered with the ongoing trials is the one concerning maintenance. So far, all the pediatric trials that have tried to shorten the maintenance therapy of this disease were able to do so without jeopardizing the final outcome. The final optimal minimal duration of therapy has yet to be established. The best therapy for a patient who has achieved a remission is still the most difficult question regarding the treatment of this disease. So far, allogeneic BMT has yielded the best results, with a disease-free interval varying between 55 and 65%. However, one-third of these patients have chronic GvHD and, therefore, a somewhat diminished quality of life. As preparative regimens and marrow purging protocols evolve, the results of autologous bone marrow transplantation seem to be improving, with disease-free intervals of 35-50% reported.